Patients With Third-Party Insurance was the largest of GeneDx Holdings Corp.’s 5 reported lines in fiscal 2025, at $1.04B — 81% of $1.27B.
| Segment | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|
| Patients With Third-Party Insurance | — | $378.80M | $694.63M | $1.04B | |||
| Institutional Customers | $138.37M | $178.49M | $195.35M | $207.14M | |||
| Diagnostic Test | — | $24.57M | $9.47M | $3.08M | |||
| Diagnostic Test Revenue | $351.25M | — | — | — | |||
| Diagnostic Test Revenue: | — | — | — | — | |||
| Other Revenue | $22.08M | $20.74M | $9.88M | $22.34M | |||
| Other Revenue (Including Related Party Revenue Of $232, $3 & $1,180 For The Years Ended December 31, 2021, 2020, And 2019, Respectively) | — | — | — | — | |||
| Self-Pay Patients | $41.83M | $10.10M | $7.03M | $4.08M | |||
| Total | $553.53M | $612.70M | $916.35M | $1.27B |
In fiscal 2025, which ended December 31, 2025, the 5 segments GeneDx Holdings Corp. reported in this breakdown added up to $1.27B. That was up 38.8% from $916.35M in fiscal 2024. Patients With Third-Party Insurance was the largest segment, at $1.04B or 81.4% of the total, followed by Institutional Customers ($207.14M, 16.3%) and Other Revenue ($22.34M, 1.8%). Together, the two largest segments made up 97.7% of this total.
Compared with fiscal 2024, Patients With Third-Party Insurance grew the fastest, rising 49.1% to $1.04B.
Diagnostic Test was first reported as a separate segment in fiscal 2023. The table also keeps 3 segments that GeneDx Holdings Corp. no longer reports, so earlier years can still be read on their original basis; use "Show 3 discontinued" beneath the table to see them. This breakdown covers every fiscal year from 2019 to 2025, as reported in GeneDx Holdings Corp.'s annual filings.
Genedx was the largest of GeneDx Holdings Corp.’s 2 reported lines in fiscal 2025, at $1.04B — 99% of $1.05B.
| Statement Business Segments | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|
| Genedx | $340.93M | $378.80M | $694.63M | $1.04B |
| Legacy Sema4 | $318.31M | — | — | — |
| Other | — | $24.68M | $9.47M | $13.35M |
| Total | $659.24M | $403.47M | $704.10M | $1.05B |
In fiscal 2025, which ended December 31, 2025, the 2 segments GeneDx Holdings Corp. reported in this breakdown added up to $1.05B. That is less than the $1.27B in its breakdown by segment, so these segments do not account for all of its revenue that year. Genedx was the largest segment, at $1.04B or 98.7% of the total, followed by Other ($13.35M, 1.3%).
Other was first reported as a separate segment in fiscal 2023. The table also keeps 1 segment that GeneDx Holdings Corp. no longer reports, so earlier years can still be read on their original basis; use "Show 1 discontinued" beneath the table to see them. This breakdown covers every fiscal year from 2022 to 2025, as reported in GeneDx Holdings Corp.'s annual filings.
GeneDx Holdings Corp. (WGS) breaks its revenue down by segment. In fiscal 2025, its largest segment was Patients With Third-Party Insurance, with $1.04B or 81.4% of the total, followed by Institutional Customers at $207.14M (16.3%).
Patients With Third-Party Insurance was GeneDx Holdings Corp.'s largest segment in fiscal 2025, with $1.04B in revenue, 81.4% of the $1.27B reported across its 5 segments.
Of the GeneDx Holdings Corp. segments reported in both fiscal 2024 and fiscal 2025, and making up at least 2% of the total, Patients With Third-Party Insurance grew the fastest, rising 49.1% from $694.63M to $1.04B.
Every figure is taken from GeneDx Holdings Corp.'s annual financial filings and shown as reported: each line keeps the name the company gives it, years follow its own fiscal calendar, and lines it has stopped reporting stay in the table for the years they were reported.
The breakdown by segment covers fiscal 2019 to 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.